![]() ![]() The induced pluripotent stem cells (iPSCs) segment is predicted to grow at a CAGR of 10% between 2023 to 2032.By product, the adult stem cells (ASCs) segment has reached 86.1% revenue share in 2022.Moreover, researchers are also discovering novel therapies for cardiac problems, arthritis, diabetes, spinal cord injury, autoimmune disorders and many more. To overcome this problem and to improve life expectancies of cancer patients, researchers are constantly working on stem cell therapy. Even though, chemotherapy is one of the effective tools used to treat cancers, it has some serious side effects which kills bone marrow, and further leads to the death of a patient. Market players are investing more in oncology to provide better clinical solutions to cancer patients. Very few treatments have been approved by regulatory bodies and also require specific criteria to meet before a patient undergoes the treatment. Almost all the stem cell therapies are still into research phase. Furthermore, embryonic stem cells can form a whole new organ. In addition, their unspecialized nature enables them to become varied variety of tissue types which makes them able to use in regenerative medicine. Stem cells are found in human body in an early stage of life as well as in adults and can differentiate into specialized cells types of a tissue or an organ.Įnormous amounts are being invested into stem cell therapy research since more than 50 years because of its unique property to divide and replicate over and over again. Stem cells have remarkable ability to renew themselves within the body. Access our Premium Real Time Data Intelligence Tool, Visit: Precedence Statistics
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |